Comment on What a drugmaker can learn from patients

What a drugmaker can learn from patients

Japanese pharmaceutical company Eisai innovates by prioritizing patient needs From the research and development of a symptomatic treatment in the 1980’s, to its continued development of anti-amyloid-beta and anti-tau antibodies, Eisai has built its rich neurology pipeline during the past four decades. Even when faced with complexities and challenges that caused others to exit the effort, Eisai has never given up on developing therapeutic solutions for families living with AD and other neurogenerative diseases. 

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News